Facebook
Twitter
Telegram
Report an ErrorEagle Pharmaceuticals Balance Sheet 2011-2024 | EGRX
Annual Balance Sheet Eagle Pharmaceuticals
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
2.43 M | - | -76.9 M | -71.2 M | -34.4 M | -66.9 M | -52.8 M | -79.1 M | -22.7 M | -10.5 M | 3.5 M | - |
Long Term Debt |
56.2 M | - | 25.1 M | 33.6 M | 38.2 M | 42.9 M | - | - | - | - | - | - |
Long Term Debt Current |
1.53 M | 1.31 M | 1.12 M | 5 M | 6.25 M | 4.88 M | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | 36.6 M | 38.2 M | 43.6 M | 22.1 M | - | - | 1.71 M | 655 K | - |
Total Current Liabilities |
111 M | 74.4 M | 38.1 M | 38.8 M | 39.7 M | 47.3 M | 41 M | 34.3 M | 22.2 M | - | - | - |
Total Liabilities |
173 M | 77.3 M | 67.2 M | 75.4 M | 77.8 M | 90.9 M | 63.1 M | 34.3 M | 20.3 M | 16 M | 21.5 M | - |
Deferred Revenue |
- | - | - | - | - | - | - | 6 M | 6.58 M | 10 M | 9.5 M | - |
Retained Earnings |
112 M | 75.9 M | 84.5 M | 72.5 M | 58.2 M | 26.3 M | -25.7 M | -107 M | -104 M | -102 M | -95.5 M | - |
Total Assets |
406 M | 254 M | 253 M | 255 M | 239 M | 270 M | 214 M | 125 M | 53.4 M | 18.1 M | 9.44 M | - |
Cash and Cash Equivalents |
55.3 M | 97.7 M | 103 M | 110 M | 78.8 M | 115 M | 52.8 M | 79.1 M | 34.9 M | 9.97 M | 5.07 M | - |
Book Value |
234 M | 176 M | 186 M | 179 M | 161 M | 179 M | 151 M | 90.3 M | 33.1 M | 2.05 M | -12.1 M | - |
Total Shareholders Equity |
234 M | 176 M | 186 M | 179 M | 161 M | 179 M | 151 M | 90.3 M | 27.9 M | -87.9 M | -93.4 M | - |
All numbers in USD currency
Quarterly Balance Sheet Eagle Pharmaceuticals
| 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
61.9 M | 68.8 M | 56.2 M | 26.4 M | 28 M | 24 M | - | 19.5 M | 21.4 M | 23.3 M | 25.1 M | 25.1 M | 25.1 M | 25.1 M | 33.6 M | 33.6 M | 33.6 M | 33.6 M | 38.2 M | 38.2 M | 38.2 M | 38.2 M | 42.9 M | 42.9 M | 42.9 M | 42.9 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
153 M | 171 M | 173 M | 155 M | 144 M | 104 M | 77.3 M | 71 M | 69.4 M | 68.9 M | 67.2 M | 67.2 M | 67.2 M | 67.2 M | 75.4 M | 75.4 M | 75.4 M | 75.4 M | 77.8 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Deferred Revenue |
- | - | - | - | - | - | - | 3.05 M | 4.34 M | 4.32 M | 4.97 M | 7.12 M | 4.97 M | 4.97 M | 8.36 M | 10.4 M | 8.36 M | 8.36 M | 5.87 M | - | 5.87 M | - | - | - | - | - | - | - | - | - | 6 M | 6 M | 6 M | 6 M | 6.52 M | 6.52 M | 6.52 M | 6.52 M | - | 10 M | 10 M | - | - | - | - | - | - | - | - | - |
Retained Earnings |
122 M | 117 M | 112 M | 103 M | 110 M | 120 M | 75.9 M | 82.1 M | 87.7 M | 84.1 M | 84.5 M | 84.5 M | 84.5 M | 84.5 M | 72.5 M | 72.5 M | 72.5 M | 72.5 M | 58.2 M | 58.2 M | 58.2 M | 58.2 M | 26.3 M | 26.3 M | 26.3 M | 26.3 M | -25.7 M | -25.7 M | -25.7 M | -25.7 M | -107 M | -107 M | -107 M | -107 M | -110 M | -110 M | -110 M | -110 M | - | -102 M | -102 M | - | - | - | - | - | - | - | - | - |
Total Assets |
405 M | 414 M | 406 M | 386 M | 382 M | 320 M | 254 M | 256 M | 264 M | 260 M | 253 M | 253 M | 253 M | 253 M | 255 M | 255 M | 255 M | 255 M | 239 M | 239 M | 239 M | 239 M | 270 M | 270 M | 270 M | 270 M | 214 M | 214 M | 214 M | 214 M | 125 M | 125 M | 125 M | 125 M | 50.1 M | 50.1 M | 50.1 M | 50.1 M | - | 18.1 M | 18.1 M | - | - | - | - | - | - | - | - | - |
Cash and Cash Equivalents |
15.4 M | 21.9 M | 55.3 M | 15.4 M | 36.6 M | 69.5 M | 97.7 M | 99.7 M | 109 M | 105 M | 103 M | 103 M | 103 M | 103 M | 110 M | 110 M | 110 M | 110 M | 78.8 M | 78.8 M | 78.8 M | 78.8 M | 115 M | 115 M | 115 M | 115 M | 52.8 M | 52.8 M | 52.8 M | 52.8 M | 79.1 M | 79.1 M | 79.1 M | 79.1 M | 34.9 M | 34.9 M | 34.9 M | 34.9 M | 9.97 M | 10.5 M | 10.5 M | 3.65 M | - | 5.07 M | - | - | - | 8.1 M | - | - |
Book Value |
252 M | 243 M | 234 M | 232 M | 238 M | 216 M | 176 M | 185 M | 195 M | 191 M | 186 M | 186 M | 186 M | 186 M | 179 M | 179 M | 179 M | 179 M | 161 M | 239 M | 239 M | 239 M | 270 M | 270 M | 270 M | 270 M | 214 M | 214 M | 214 M | 214 M | 125 M | 125 M | 125 M | 125 M | 50.1 M | 50.1 M | 50.1 M | 50.1 M | - | 18.1 M | 18.1 M | - | - | - | - | - | - | - | - | - |
Total Shareholders Equity |
252 M | 243 M | 234 M | 232 M | 238 M | 216 M | 176 M | 185 M | 195 M | 191 M | 186 M | 186 M | 186 M | 186 M | 179 M | 179 M | 179 M | 179 M | 161 M | 161 M | 161 M | 161 M | 179 M | 179 M | 179 M | 179 M | 151 M | 151 M | 151 M | 151 M | 90.3 M | 90.3 M | 90.3 M | 90.3 M | 27.9 M | 27.9 M | 27.9 M | 27.9 M | - | -87.9 M | -87.9 M | - | - | -93.4 M | - | - | - | -71.2 M | - | - |
All numbers in USD currency